Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/JBCHEPHARM stock hub

NSE/JBCHEPHARM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/JBCHEPHARMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

345.5B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/JBCHEPHARM

In the news

Latest news · NSE/JBCHEPHARM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E38.4

P25 24.9P50 32.4P75 45.7

Trailing P/E45.8

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC21.9

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/JBCHEPHARM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

200

Groups with data

Currency

INR

Showing 200 of 200 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	5,304
Employees Change	-7%
Employees Change Percent	-0.13
Enterprise value	INR 340B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE572A01036
Last refreshed	2026-05-10
Market cap	INR 345.5B
Price	INR 2,153
Price currency	INR
Rev Per Employee	7,905,427.22x
Sector	Healthcare
Sic	2834
Symbol	nse/JBCHEPHARM
Website	https://www.jbpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.18%
EV Earnings	45.1x
EV/EBIT	35.67x
EV/EBITDA	29.64x
EV/Sales	8.11x
Forward P/E	38.35x
P/B ratio	9.08x
P/E ratio	45.84x
P/S ratio	8.24x
PE Ratio10 Y	25.76x
PE Ratio3 Y	42.6x
PE Ratio5 Y	38.3x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	22.73%
EBITDA Margin	27.09%
Gross margin	67.05%
Gross Profit	INR 28.1B
Gross Profit Growth	12.33%
Gross Profit Growth Q	13.69%
Gross Profit Growth3 Y	14.3%
Gross Profit Growth5 Y	17.01%
Net Income	INR 7.5B
Net Income Growth	17.77%
Net Income Growth Q	21.79%
Net Income Growth Quarters	14%
Net Income Growth Years	3%
Net Income Growth3 Y	22.8%
Net Income Growth5 Y	13.65%
Pretax Margin	24.1%
Profit Margin	17.98%
Profit Per Employee	INR 1.4M
Profitable Years	21
Roa5y	12.96
Roe5y	21.22
ROIC	21.85
Roic5y	22.72

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	34.59%
Cagr15y	29.78%
Cagr1y	41.58%
Cagr20y	24.07%
Cagr3y	29.58%
Cagr5y	25.33%
Div CAGR10	7.85%
Div CAGR3	33.66%
Div CAGR5	32.91%
EPS Growth	18.07
EPS Growth Q	21.58
EPS Growth Quarters	9
EPS Growth Years	3
EPS Growth3 Y	22.02
EPS Growth5 Y	13.06
Revenue Growth	9.47x
Revenue Growth Q	10.51x
Revenue Growth Quarters	21x
Revenue Growth Years	13x
Revenue Growth3 Y	11.66x
Revenue Growth5 Y	16.46x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 5.9B
Debt	INR 409.1M
Debt EBITDA	INR 0.04
Debt Equity	INR 0.01
Equity	INR 38.1B
Interest Coverage	202.6
Net Cash	INR 5.5B
Net Cash By Market Cap	INR 1.6
Net Cash Growth	74.72%
Net Debt EBITDA	INR -0.49
Net Debt Equity	INR -0.15
Tangible Book Value	INR 24.8B
Tangible Book Value Per Share	INR 158
WACC	4.04

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.27%
Dividend Growth	29.18%
Dividend Growth Years	3%
Dividend per share	INR 19.7
Dividend Years	24
Dividend Yield	0.92%
Ex Div Date	2026-02-11
Last Dividend	INR 12.7
Payout Frequency	Semi-Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	1,848.87%
1Y total return	41.55%
200-day SMA	1,839.9
3Y total return	117.59%
50-day SMA	2,052
50-day SMA vs 200-day SMA	50over200
5Y total return	209.22%
All Time High	2,195
All Time High Change	-1.94%
All Time High Date	2026-03-20
All Time Low	12.75
All Time Low Change	16,782.35%
All Time Low Date	2008-10-08
ATR	48.53
Beta	-0.04
Ch YTD	18.29
High	2,164
High52	2,195
High52 Date	2026-03-20
High52ch	-1.94%
Low	2,134.9
Low52	1,510.1
Low52 Date	2025-05-09
Low52ch	43.87%
Ma50ch	4.9%
Price vs 200-day SMA	16.99%
RSI	69.26
RSI Monthly	71.25
RSI Weekly	68.43
Sharpe ratio	1.36x
Sortino ratio	2.45
Total Return	1.18%
Tr YTD	19.08
Tr15y	4,888.45%
Tr1m	9.72%
Tr1w	3.38%
Tr3m	17.16%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 9.5B
Operating Income Growth	14.27
Operating Income Growth Q	17.83
Operating Income Growth3 Y	19.69
Operating Income Growth5 Y	15.19
Operating margin	22.73

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	81,503,880%
Shares Insiders	0.13%
Shares Institutions	31.55%
Shares Qo Q	0.04%
Shares Yo Y	-0.27%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	297,795.55x
Bv Per Share	243.4
Ch10y	1,669.4
Ch15y	2,700
Ch1m	9.72
Ch1w	3.38
Ch1y	40.06
Ch20y	3,673
Ch3m	16.38
Ch3y	112.1
Ch5y	195.8
Ch6m	26.4
Change	0.43%
Change From Open	0.43
Close	2,143.2
Days Gap	0
Depreciation Amortization	1,826,581,750
Dollar Volume	292,423,582.5
Earnings Date	2026-05-11
EBIT	INR 9.5B
EBITDA	INR 11.4B
EPS	INR 47.47
F Score	2
Fiscal Year End	March
Founded	1,976
Graham Number	500.52265
Graham Upside	-76.75
Income Tax	INR 2.6B
Is Primary Listing	0
Last Earnings Date	2026-01-16
Last Report Date	2025-12-31
Last Split Date	2023-09-18
Last Split Type	Forward
Lynch Fair Value	INR 641
Lynch Upside	-70.21
Ma150	1,883
Ma150ch	14.31%
Ma20	2,035.7
Ma20ch	5.74%
Next Earnings Date	2026-05-11
Open	2,143.3
Payment Date	2026-03-07
Position In Range	60.48
Price Date	2026-05-08
Price EBITDA	INR 30.42
Ptbv Ratio	13.96
Relative Volume	0.42x
Revenue	41,930,386,000x
Tax By Revenue	6.13x
Tax Rate	25.42%
Tr20y	7,366.74%
Tr6m	27.24%
Volume	135,853

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/JBCHEPHARM dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.9%

$19.7 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+32.9%

3 consecutive years of growth

Total shareholder yield

+1.2%

Next ex-dividend date: 2026-02-11

Performance

NSE/JBCHEPHARM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/JBCHEPHARM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+31.6%

Share of float held by funds and institutions

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.3%

Negative means the company is buying back shares.

Technical

NSE/JBCHEPHARM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

69.3

Neutral momentum band

Price vs 200-day MA

+17.0%

50/200-day relationship not available

Beta (5Y)

-0.04

Less volatile than the market

Sharpe ratio

1.35

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/JBCHEPHARM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/JBCHEPHARM stock rating?

nse/JBCHEPHARM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/JBCHEPHARM analysis?

The full report lives at /stocks/nse/JBCHEPHARM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/JBCHEPHARM?

The latest report frames nse/JBCHEPHARM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/JBCHEPHARM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.